Published in Cancer Res on February 09, 2010
Tumor metastasis: molecular insights and evolving paradigms. Cell (2011) 10.34
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov (2013) 2.93
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov (2014) 2.51
Diversification of TAM receptor tyrosine kinase function. Nat Immunol (2014) 2.12
VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res (2011) 1.92
The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci Signal (2013) 1.92
Controlling escape from angiogenesis inhibitors. Nat Rev Cancer (2012) 1.81
Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets (2010) 1.76
Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer. Proc Natl Acad Sci U S A (2013) 1.64
Biology of the TAM receptors. Cold Spring Harb Perspect Biol (2013) 1.59
AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res (2010) 1.50
Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation. J Hepatol (2015) 1.46
Retracted Activation of miR-31 function in already-established metastases elicits metastatic regression. Genes Dev (2011) 1.40
Axl is essential for VEGF-A-dependent activation of PI3K/Akt. EMBO J (2012) 1.38
Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene (2012) 1.33
Axl-dependent signalling: a clinical update. Clin Sci (Lond) (2012) 1.28
AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene (2013) 1.27
First Axl inhibitor enters clinical trials. Nat Biotechnol (2013) 1.22
AXL mediates resistance to cetuximab therapy. Cancer Res (2014) 1.20
Vimentin: Central hub in EMT induction? Small GTPases (2011) 1.20
TAM receptor signaling in immune homeostasis. Annu Rev Immunol (2015) 1.18
The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene (2012) 1.17
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell (2015) 1.14
Targeting Axl with an high-affinity inhibitory aptamer. Mol Ther (2012) 1.14
The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther (2010) 1.12
Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities. Elife (2014) 1.11
Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays. Oncogene (2012) 1.10
Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci U S A (2016) 1.08
AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clin Cancer Res (2013) 1.06
The TAM receptor Mertk protects against neuroinvasive viral infection by maintaining blood-brain barrier integrity. Nat Med (2015) 1.02
Axl phosphorylates Elmo scaffold proteins to promote Rac activation and cell invasion. Mol Cell Biol (2014) 1.02
Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer. Mol Cancer Res (2012) 0.99
Axl as a mediator of cellular growth and survival. Oncotarget (2014) 0.99
Lactate engages receptor tyrosine kinases Axl, Tie2, and vascular endothelial growth factor receptor 2 to activate phosphoinositide 3-kinase/Akt and promote angiogenesis. J Biol Chem (2013) 0.99
Role of the blood-brain barrier in the formation of brain metastases. Int J Mol Sci (2013) 0.96
Mesenchymal Cancer Cell-Stroma Crosstalk Promotes Niche Activation, Epithelial Reversion, and Metastatic Colonization. Cell Rep (2015) 0.96
Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction. Cancer Biol Ther (2013) 0.96
An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis. Nat Chem Biol (2014) 0.96
Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention. Front Oncol (2014) 0.95
Molecular pathways: niches in metastatic dormancy. Clin Cancer Res (2014) 0.95
AMPK activation through mitochondrial regulation results in increased substrate oxidation and improved metabolic parameters in models of diabetes. PLoS One (2013) 0.94
TAM receptors in leukemia: expression, signaling, and therapeutic implications. Crit Rev Oncog (2011) 0.94
Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance. Cancer Discov (2016) 0.94
Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. ACS Med Chem Lett (2011) 0.93
PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model. PLoS One (2012) 0.91
Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies. Int J Mol Sci (2014) 0.91
Prostaglandin E₂ induces oncostatin M expression in human chronic wound macrophages through Axl receptor tyrosine kinase pathway. J Immunol (2012) 0.90
An in vivo model of epithelial to mesenchymal transition reveals a mitogenic switch. Cancer Lett (2012) 0.89
The AXL Receptor is a Sensor of Ligand Spatial Heterogeneity. Cell Syst (2015) 0.88
AXL-Mediated Productive Infection of Human Endothelial Cells by Zika Virus. Circ Res (2016) 0.87
Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy. Neoplasia (2014) 0.87
Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase. PLoS One (2012) 0.87
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res (2015) 0.87
The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma. Int J Clin Exp Pathol (2014) 0.87
Advances in targeted therapies and new promising targets in esophageal cancer. Oncotarget (2015) 0.87
Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling. Theranostics (2016) 0.87
Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents. Oncogene (2015) 0.86
Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis. Cancer Res (2015) 0.86
The Axl receptor tyrosine kinase is a discriminator of macrophage function in the inflamed lung. Mucosal Immunol (2015) 0.86
ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT. Oncogene (2015) 0.85
The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma. Oncotarget (2014) 0.85
Local lung hypoxia determines epithelial fate decisions during alveolar regeneration. Nat Cell Biol (2017) 0.85
Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells. Oncotarget (2015) 0.84
Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells. Stem Cell Reports (2015) 0.84
Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation. J Biol Chem (2013) 0.83
Axl receptor tyrosine kinase expression in breast cancer. J Clin Pathol (2014) 0.82
Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines. Oncogenesis (2012) 0.81
Critical signal transduction pathways in CLL. Adv Exp Med Biol (2013) 0.81
Janus kinase 1/3 signaling pathways are key initiators of TH2 differentiation and lung allergic responses. J Allergy Clin Immunol (2013) 0.81
Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells. Cancer Biol Ther (2014) 0.81
Novel tyrosine kinase signaling pathways: implications in vascular remodeling. Curr Opin Nephrol Hypertens (2012) 0.81
A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics. Dis Model Mech (2015) 0.81
VEGF-A engages at least three tyrosine kinases to activate PI3K/Akt. Cell Cycle (2012) 0.80
ΔNp63α Promotes Breast Cancer Cell Motility through the Selective Activation of Components of the Epithelial-to-Mesenchymal Transition Program. Cancer Res (2015) 0.80
Tandem phosphorylation within an intrinsically disordered region regulates ACTN4 function. Sci Signal (2015) 0.80
Inactivation of GSK3β and activation of NF-κB pathway via Axl represents an important mediator of tumorigenesis in esophageal squamous cell carcinoma. Mol Biol Cell (2015) 0.80
Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies. J Clin Invest (2016) 0.79
Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase. Cell Commun Signal (2016) 0.79
Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells. Oncotarget (2015) 0.78
Mechanosensing Controlled Directly by Tyrosine Kinases. Nano Lett (2016) 0.78
Axl-targeted cancer imaging with humanized antibody h173. Mol Imaging Biol (2014) 0.78
Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells. Oncogenesis (2016) 0.77
TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunol Rev (2017) 0.77
Strong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer. PLoS One (2016) 0.76
Molecular insights of Gas6/TAM in cancer development and therapy. Cell Death Dis (2017) 0.76
AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas. BMC Cancer (2015) 0.76
Axl Expression Stratifies Patients with Poor Prognosis after Hepatectomy for Hepatocellular Carcinoma. PLoS One (2016) 0.76
In vitro and in vivo antiangiogenic activity of desacetylvinblastine monohydrazide through inhibition of VEGFR2 and Axl pathways. Am J Cancer Res (2016) 0.76
Coordinated expression of tyro3, axl, and mer receptors in macrophage ontogeny. Macrophage (Houst) (2016) 0.76
MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells. PLoS One (2015) 0.76
AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer. Oncotarget (2016) 0.76
A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer. Oncotarget (2016) 0.75
Regulated intramembrane proteolysis of the AXL receptor kinase generates an intracellular domain that localizes in the nucleus of cancer cells. FASEB J (2016) 0.75
Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression. Int J Mol Sci (2016) 0.75
The Receptor Tyrosine Kinase AXL in Cancer Progression. Cancers (Basel) (2016) 0.75
Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL. Oncotarget (2017) 0.75
Ligand Activation of TAM Family Receptors-Implications for Tumor Biology and Therapeutic Response. Cancers (Basel) (2016) 0.75
Targeting the TAM Receptors in Leukemia. Cancers (Basel) (2016) 0.75
A mitochondrial protein compendium elucidates complex I disease biology. Cell (2008) 13.51
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A (2010) 8.05
Astrocytic purinergic signaling coordinates synaptic networks. Science (2005) 6.55
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature (2008) 6.04
Systematic identification of human mitochondrial disease genes through integrative genomics. Nat Genet (2006) 4.67
Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature (2010) 4.38
Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol (2007) 4.12
New world bats harbor diverse influenza A viruses. PLoS Pathog (2013) 4.10
Wdr5 mediates self-renewal and reprogramming via the embryonic stem cell core transcriptional network. Cell (2011) 4.04
Early repolarization pattern and risk for arrhythmia death: a meta-analysis. J Am Coll Cardiol (2013) 4.03
An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J (2010) 3.90
Antagonistic regulation of PIN phosphorylation by PP2A and PINOID directs auxin flux. Cell (2007) 3.84
Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci U S A (2011) 3.80
Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J (2005) 3.60
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Mice genetically deficient in vasopressin V1a and V1b receptors are resistant to jet lag. Science (2013) 3.51
R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther (2006) 3.46
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Induction of a hemogenic program in mouse fibroblasts. Cell Stem Cell (2013) 2.71
Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells. Glia (2005) 2.68
Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res (2008) 2.59
HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene (2005) 2.53
MicroRNA identification based on sequence and structure alignment. Bioinformatics (2005) 2.52
ABP1 mediates auxin inhibition of clathrin-dependent endocytosis in Arabidopsis. Cell (2010) 2.51
Approaches for high internal quantum efficiency green InGaN light-emitting diodes with large overlap quantum wells. Opt Express (2011) 2.44
Discovering patterns to extract protein-protein interactions from full texts. Bioinformatics (2004) 2.42
Subcellular homeostasis of phytohormone auxin is mediated by the ER-localized PIN5 transporter. Nature (2009) 2.40
Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes (2003) 2.36
Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood (2008) 2.33
In vitro derivation of functional insulin-producing cells from human embryonic stem cells. Cell Res (2007) 2.28
Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res (2009) 2.20
Automatic detection and recognition of signs from natural scenes. IEEE Trans Image Process (2004) 2.19
Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood (2005) 2.17
Sperm, but not oocyte, DNA methylome is inherited by zebrafish early embryos. Cell (2013) 2.16
A new algorithm for the evaluation of shotgun peptide sequencing in proteomics: support vector machine classification of peptide MS/MS spectra and SEQUEST scores. J Proteome Res (2003) 2.16
Hand, foot, and mouth disease in China: patterns of spread and transmissibility. Epidemiology (2011) 2.13
In vivo photodynamic therapy using upconversion nanoparticles as remote-controlled nanotransducers. Nat Med (2012) 2.13
Accurate inclusion mass screening: a bridge from unbiased discovery to targeted assay development for biomarker verification. Mol Cell Proteomics (2008) 2.11
A novel 3D mammalian cell perfusion-culture system in microfluidic channels. Lab Chip (2007) 2.03
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Current management of gall bladder perforations. ANZ J Surg (2004) 1.99
Altered heart rate variability depend on the characteristics of coronary lesions in stable angina pectoris. Anatol J Cardiol (2014) 1.97
Reinvestigation of the role of humic acid in the oxidation of phenols by permanganate. Environ Sci Technol (2013) 1.96
Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res (2002) 1.93
Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol (2007) 1.91
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Multiple roles for the receptor tyrosine kinase axl in tumor formation. Cancer Res (2005) 1.87
Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. Blood (2010) 1.86
Structural basis of ultraviolet-B perception by UVR8. Nature (2012) 1.86
Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum (2004) 1.82
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res (2004) 1.82
Structure of the CRISPR interference complex CSM reveals key similarities with cascade. Mol Cell (2013) 1.74
Targeted disruption of hsf1 leads to lack of thermotolerance and defines tissue-specific regulation for stress-inducible Hsp molecular chaperones. J Cell Biochem (2002) 1.73
Framework for performance evaluation of face, text, and vehicle detection and tracking in video: data, metrics, and protocol. IEEE Trans Pattern Anal Mach Intell (2009) 1.72
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner. Blood (2011) 1.70
Bariatric surgery reduces visceral adipose inflammation and improves endothelial function in type 2 diabetic mice. Arterioscler Thromb Vasc Biol (2011) 1.69
Matrix metalloproteinase 2 activation of transforming growth factor-beta1 (TGF-beta1) and TGF-beta1-type II receptor signaling within the aged arterial wall. Arterioscler Thromb Vasc Biol (2006) 1.69
Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth. Mol Biol Cell (2005) 1.68
Rat aortic MCP-1 and its receptor CCR2 increase with age and alter vascular smooth muscle cell function. Arterioscler Thromb Vasc Biol (2004) 1.68
Enhance the optical absorptivity of nanocrystalline TiO2 film with high molar extinction coefficient ruthenium sensitizers for high performance dye-sensitized solar cells. J Am Chem Soc (2008) 1.68
Direct differentiation of atrial and ventricular myocytes from human embryonic stem cells by alternating retinoid signals. Cell Res (2010) 1.67
Conventional US, US elasticity imaging, and acoustic radiation force impulse imaging for prediction of malignancy in thyroid nodules. Radiology (2014) 1.67
Attitudes of Canadian nephrologists, family physicians and patients with kidney failure toward primary care delivery for chronic dialysis patients. Nephrol Dial Transplant (2003) 1.66
Proinflammatory profile within the grossly normal aged human aortic wall. Hypertension (2007) 1.66
c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D. Leuk Res (2009) 1.64
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem (2013) 1.63
Resveratrol improves endothelial function: role of TNF{alpha} and vascular oxidative stress. Arterioscler Thromb Vasc Biol (2009) 1.63
Hypertension alters GABA receptor-mediated inhibition of neurons in the nucleus of the solitary tract. Am J Physiol Regul Integr Comp Physiol (2003) 1.63
Toll-like receptor 3 agonist poly(I:C)-induced antiviral response in human corneal epithelial cells. Immunology (2006) 1.63
Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids (2004) 1.63
Toll-like receptor 2-mediated expression of beta-defensin-2 in human corneal epithelial cells. Microbes Infect (2005) 1.62
Cideb regulates diet-induced obesity, liver steatosis, and insulin sensitivity by controlling lipogenesis and fatty acid oxidation. Diabetes (2007) 1.62
Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol (2008) 1.61
A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther (2006) 1.60
RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix. Mol Cell Biol (2002) 1.60
Interpretation of urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine is adversely affected by methodological inaccuracies when using a commercial ELISA. Free Radic Biol Med (2010) 1.60
Fine mapping and identification of a candidate gene SSH1 in disseminated superficial actinic porokeratosis. Hum Mutat (2004) 1.59
Neuregulin 1 regulates excitability of fast-spiking neurons through Kv1.1 and acts in epilepsy. Nat Neurosci (2011) 1.58
Evidence of recombination and genetic diversity in human rhinoviruses in children with acute respiratory infection. PLoS One (2009) 1.58
Oil palm (Elaeis guineensis Jacq.) tissue culture ESTs: identifying genes associated with callogenesis and embryogenesis. BMC Plant Biol (2008) 1.57
Identification of the Syk kinase inhibitor R112 by a human mast cell screen. J Allergy Clin Immunol (2006) 1.54
Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling. Cell Stem Cell (2012) 1.54
Wound-induced ATP release and EGF receptor activation in epithelial cells. J Cell Sci (2007) 1.54
SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol (2010) 1.54
Innate immune response of corneal epithelial cells to Staphylococcus aureus infection: role of peptidoglycan in stimulating proinflammatory cytokine secretion. Invest Ophthalmol Vis Sci (2004) 1.53
Immunization status and risk factors of migrant children in densely populated areas of Beijing, China. Vaccine (2009) 1.53
Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain (2011) 1.53
Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol (2013) 1.52
Development and application of a broadly sensitive dried-blood-spot-based genotyping assay for global surveillance of HIV-1 drug resistance. J Clin Microbiol (2010) 1.52